GENERAL DISCUSSION 229 10 68. Scher AI, Terwindt GM, Picavet HS, et al. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology. 2005;64(4):614-620. 69. Hagen K, Åsberg AN, Stovner L, et al. Lifestyle factors and risk of migraine and tension-type headache. Follow-up data from the NordTrøndelag Health Surveys 1995-1997 and 20062008. Cephalalgia. 2018;38(13):1919-1926. 70. Le H, Tfelt-Hansen P, Skytthe A, Kyvik KO, Olesen J. Association between migraine, lifestyle and socioeconomic factors: a populationbased cross-sectional study. J Headache Pain. 2011;12(2):157-172. 71. Pourhoseingholi MA, Baghestani AR, Vahedi M. How to control confounding effects by statistical analysis. Gastroenterol Hepatol Bed Bench. 2012;5(2):79-83. 72. McNamee R. Regression modelling and other methods to control confounding. Occup Environ Med. 2005;62(7):500-6, 472. 73. Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology. 2018;43(1):155-172. 74. Engeli S,Böhnke J,Feldpausch M,et al.Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54(10):2838-2843. 75. Piyanova A, Lomazzo E, Bindila L, et al. Agerelated changes in the endocannabinoid system in the mouse hippocampus. Mech Ageing Dev. 2015;150:55-64. 76. Hill MN,Miller GE,Ho WS,Gorzalka BB,Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry. 2008;41(2):48-53. 77. Kranaster L, Hoyer C, Aksay SS, et al. Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. Eur Arch Psychiatry Clin Neurosci. 2017;267(8):781-786. 78. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology. 2009;34(8):1257-1262. 79. Patel S, Hillard CJ. Role of endocannabinoid signaling in anxiety and depression. Curr Top Behav Neurosci. 2009;1:347-371. 80. Gallego-Landin I, García-Baos A, CastroZavala A, Valverde O. Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression. Review. Front Pharmacol. 2021;12 81. Smaga I, Bystrowska B, Gawliński D, Przegaliński E, Filip M.The endocannabinoid/ endovanilloid system and depression. Curr Neuropharmacol. 2014;12(5):462-474. 82. Piazza PV, Cota D, Marsicano G. The CB1 Receptor as the Cornerstone of Exostasis. Neuron. 2017;93(6):1252-1274. 83. Blüher M, Engeli S, Klöting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55(11):30533060. 84. Wagner EJ. Sex differences in cannabinoidregulated biology: A focus on energy homeostasis. Front Neuroendocrinol. 2016;40:101-109. 85. Rubino T, Parolaro D. Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. Front Behav Neurosci. 2011;5:64. 86. Craft RM, Marusich JA, Wiley JL. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci. 2013;92(8-9):476-481. 87. Alvarez-Jaimes L, Stouffer DG, Parsons LH. Chronic ethanol treatment potentiates ethanol-induced increases in interstitial nucleus accumbens endocannabinoid levels in rats. J Neurochem. 2009;111(1):37-48. 88. Basavarajappa BS, Hungund BL. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem. 1999;72(2):522528. 89. Vinod KY, Yalamanchili R, Xie S, Cooper TB, Hungund BL. Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system. Neurochem Int. 2006;49(6):619-625.
RkJQdWJsaXNoZXIy MTk4NDMw